Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies  Federico Moscardó, Jaime Sanz, Francisco.

Slides:



Advertisements
Similar presentations
Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia Jaime Sanz, Pau Montesinos,
Advertisements

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia  Jaime Sanz, Pau Montesinos,
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:
Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen  Jaime Sanz,
Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture  John E. Wagner,
Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation 
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Vaccination of Children following Allogeneic Stem Cell Transplantation
Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk.
Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture  John E. Wagner,
Total Colony-Forming Units Are a Strong, Independent Predictor of Neutrophil and Platelet Engraftment after Unrelated Umbilical Cord Blood Transplantation:
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft.
Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted.
Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications  Koen Van Besien, Hongtao Liu, Nitin Jain,
HLA-Haploidentical T Cell–Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia  Marco Zecca, Luisa Strocchio, Daria.
Sabina Kersting, Leo F. Verdonck 
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation  Jaime Sanz, Alessandra.
Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years  Masatsugu Tanaka, Koichi Miyamura,
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources  Christopher M. Walker,
Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302  Javier Bolaños-Meade, Juan Wu, Brent R. Logan,
A “No-wash” Albumin-Dextran Dilution Strategy for Cord Blood Unit Thaw: High Rate of Engraftment and a Low Incidence of Serious Infusion Reactions  Juliet.
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation:
Influence of Nucleated Cell Dose on Overall Survival of Unrelated Cord Blood Transplantation for Patients with Severe Acquired Aplastic Anemia: A Study.
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Mats Remberger, Johan Törlén, Olle.
Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning 
Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.
Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.
Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia 
Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.
Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients  Irene Schmid, Daniel Stachel,
Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses  Seitaro Terakura, Eiichi.
Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses.
Early and Late Neurological Complications after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation  Pere Barba, Jose Luis Piñana, David.
Analysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced  Robert Chow, Auayporn Nademanee,
Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pauline Damien, David S. Allan 
Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in.
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation  Mohammed M. Elayan, Justin G.
Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka.
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders  Mi Kwon,
Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Richard Mitchell, John E. Wagner, Claudio G
Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Blood and Marrow Transplant Handbook
T Cell–Depleted Related HLA-Mismatched Peripheral Blood Stem Cell Transplantation as Salvage Therapy for Graft Failure after Single Unit Unrelated Donor.
Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease  Haydar Frangoul, Li.
Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation  J.R. Molina,
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning  Junya Kanda, David.
Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment  Duncan Purtill,
Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Cryopreserved CD34+ Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after.
Optimal Donor Selection: Beyond HLA
Presentation transcript:

Effect of CD8+ Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies  Federico Moscardó, Jaime Sanz, Francisco Carbonell, Miguel A. Sanz, Luis Larrea, Pau Montesinos, Ignacio Lorenzo, Belén Vera, Blanca Boluda, Claudia Salazar, Carolina Cañigral, Dolores Planelles, Isidro Jarque, Pilar Solves, Guillermo Martín, Francisca López, Javier de la Rubia, Jesús Martínez, Nelly Carpio, David Martínez-Cuadrón, Nieves Puig, José A. Montoro, Roberto Roig, Guillermo F. Sanz  Biology of Blood and Marrow Transplantation  Volume 20, Issue 11, Pages 1744-1750 (November 2014) DOI: 10.1016/j.bbmt.2014.06.038 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Unadjusted cumulative incidence of myeloid engraftment in the overall series (A), and according to CD8+ cells infused × 106/kg (B), CD34+ cells infused × 105/kg (C), and both cell populations (D). For patients who received UCB units above and below 1.6 × 106 CD8+ cells/kg, the cumulative incidence of myeloid engraftment at 60 days and the median time to neutrophil recovery were 96% and 19 days and 87%, and 22 days, respectively (P = .007) (B). For patients who received UCB units above and below 1.3 × 105 CD34+ cells/kg, those figures were 92% and 18 days and 91% and 23 days, respectively (P = .005) (C). The numbers of CD34+ and CD8+ cells were able to define 4 groups regarding the speed and overall rate of myeloid engraftment (D), with group 1 being those grafts with high doses of both CD34+ cells (>1.3 × 105 per kg) and CD8+ cells (>1.6 × 106 per kg), group 2 those with high dose of CD34+ cells (>1.3 × 105 per kg) but low dose of CD8+ cells (<1.6 × 106 per kg), group 3 those with low dose of CD34+ cells (<1.3 × 105 per kg) but high dose of CD8+ cells (>1.6 × 106 per kg), and group 4 those with low doses of both CD34+ cells (<1.3 × 105 per kg) and CD8+ cells (<1.6 × 106 per kg). The cumulative incidence of and median time to myeloid engraftment were 95% and 17 days for group 1 (high rate and fast engraftment), 88% and 19 days for group 2 (low rate but fast engraftment), 97% and 23 days for group 3 (high rate but slow engraftment), and 87% and 23 days for group 4 (low rate and slow engraftment), respectively (P = .009). Biology of Blood and Marrow Transplantation 2014 20, 1744-1750DOI: (10.1016/j.bbmt.2014.06.038) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Unadjusted cumulative incidence of platelet engraftment in the overall series (A) and according to CD8+ cells infused × 106 per kg (B). For patients who received UCB units with > 1.6 × 106 CD8+ cells/kg, the cumulative incidence of platelet engraftment at 180 days and median time to platelet engraftment were 77% and 44 days, respectively, whereas for those receiving a lower CD8+ cell dose they were 57% and 62 days, respectively (P = .0001). Biology of Blood and Marrow Transplantation 2014 20, 1744-1750DOI: (10.1016/j.bbmt.2014.06.038) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Unadjusted cumulative incidence of NRM (A), DFS (B), and OS (C) according to CD8+ cells infused × 106 per kg. The cumulative incidence of NRM at 100 days, 1 year, and 4 years was 13%, 34%, and 39% for patients with CD8+ cells above 1.6 × 106 CD8+ cells per kg whereas it was 26%, 46%, and 54% for those below that level (P = .03). DFS and OS for patients with CD8+ cells above 2.2 × 106 CD8+ cells per kg were 38% and 42%, respectively compared with 23% and 26% for patients who received a lower CD8+ cell dose (P = .02 and P = .04, respectively). Biology of Blood and Marrow Transplantation 2014 20, 1744-1750DOI: (10.1016/j.bbmt.2014.06.038) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions